Search

Background: We primarily investigated the prognostic role of CDKN2A homozygous deletion in CNS WHO grade 4 gliomas. Additionally, we plan to examine traditional prognostic factors for grade 4 gliomas and validate the findings. Materials: We conducted a retrospective analysis of the glioma cohorts at our institute. We reviewed medical records spanning a 15-year period and examined pathological slides for an updated diagnosis according to the 2021 WHO classification of CNS tumors. We examined the IDH1/2 mutation and CDKN2A deletion using NGS analysis with ONCOaccuPanel®. Further, we examined traditional prognostic factors, including age, WHO performance status, extent of resection, and MGMT promoter methylation status. Results: The mean follow-up duration was 27.5 months (range: 4.1–43.5 months) and mean overall survival (OS) was 20.7 months (SD, ±1.759). After the exclusion of six patients with a poor status of pathologic samples, a total of 136 glioblastoma cases diagnosed by previous WHO classification criteria were newly classified into 29 (21.3%) astrocytoma, IDH-mutant, and CNS WHO grade 4 cases, and 107 (78.7%) glioblastoma, IDH-wildtype, and CNS WHO grade 4 cases. Among them, 61 (56.0%) had CDKN2A deletions. The high-risk group with CDKN2A deletion regardless of IDH1/2 mutation had a mean OS of 16.65 months (SD, ±1.554), the intermediate-risk group without CDKN2A deletion and with IDH1/2 mutation had a mean OS of 21.85 months (SD, ±2.082), and the low-risk group without CDKN2A deletion and with IDH1/2 mutation had a mean OS of 33.38 months (SD, ±2.946). Multifactor analysis showed that age (≥50 years vs. MGMT promoter methylation, (methylated vs. unmethylated; HR 5.078), IDH1/2 mutation (mutant vs. wildtype; HR 6.352), and CDKN2A deletion (absence vs. presence; HR 13.454) were associated with OS independently. Conclusions: The present study suggests that CDKN2A deletion plays a powerful prognostic role in CNS WHO grade 4 gliomas. Even if CNS WHO grade 4 gliomas have mutant IDH1/2, they may have poor clinical outcomes because of CDKN2A deletion.

The Radiation Therapy Oncology Group (RTOG) 9310 protocol clinical trial established high-dose methotrexate (HDMTX) as the standard for primary central nervous system lymphoma (PCNSL). We aimed to investigate the RTOG 9310 protocol’s PCNSL outcomes by examining progression-free survival (PFS) and overall survival (OS) rates and determining the influential factors. Between 2007 and 2020, 87 patients were histopathologically diagnosed with PCNSL and treated with the RTOG 9310 protocol. All received HDMTX 2.5 g/m2 and vincristine 1.4 mg/m2/day for 1 day during weeks 1, 3, 5, 7, and 9, and procarbazine 100 mg/m2/day for 1 day during weeks 1, 5, and 9. Dexamethasone was administered on a standard tapering schedule from the first week to the sixth week. Whole brain radiotherapy (WBRT), consisting of 45 Gy for patients with less than a complete response to the chemotherapy or 36 Gy for complete responders, was started 1 week after the last dose of chemotherapy was administered. Within three weeks of the completion of WBRT, patients received two courses of cytarabine, which were separated by 3–4 weeks. Clinical, radiological, and histopathological characteristics were retrospectively reviewed. All patients completed five HDMTX cycles and a mean follow-up of 60.2 (range, 6–150) months. Twenty-eight (32.2%) patients experienced recurrence during follow-up. The mean time to recurrence was 21.8 months, while the mean PFS was 104.3 (95% confidence interval (CI), 90.6–118.0) months. Eleven (12.6%) patients died; the mean OS was 132.1 (95% CI, 122.2–141.9) months. The 3- and 5-year survival rates were 92.0% and 87.4%, respectively. One patient experienced acute renal failure, while the remainder tolerated any cytotoxic side effects. On multivariate analysis, the Eastern Cooperative Oncology Group performance score ≤ 2; the International Extranodal Lymphoma Study Group low-risk status; XBP-1, p53, and c-Myc negativity; homogenous enhancement; gross total resection, independently correlated with long PFS and OS. The RTOG 9310 protocol is effective for PCNSL and features good outcomes.

A design of a modular antenna/detector array for the electron cyclotron emission (ECE) imaging system at the Korea Superconducting Tokamak Advanced Research (KSTAR) is proposed. The modular antenna/detector array is based on a unit antenna/detector module, which consists of an elliptical mini-lens, a dual-dipole antenna, an antenna balun, a low-noise amplifier, and a metal frame. The proposed modular antenna/detector array resolves the problem in the conventional antenna/detector array where one faulty channel requires the entire array to be removed for the service. With the proposed modular array, each channel module can be easily and independently removed and replaced without interference to the rest of the array, thus minimizing the interrupted service time for maintenance. Moreover, the unit channel modules can be efficiently updated under a variety of the tokamak operation conditions. The antenna/detector modules are optimized to have improved performance, and are tested in a W-band test setup, and consistently provide the gain increase by 10~20 dB as compared with the conventional antenna/detector array. A set of the proposed modular antenna/detector array is currently installed and tested in the KSTAR ECE imaging system, and will consistently produce the improved ECE imaging to monitor MHD instability activities under various plasma operation conditions.

This study proposes an unbalanced current compensation method based on a four-leg inverter using an artificial neural network (ANN) under unbalanced load conditions. Distribution systems exhibit rapid load variations, and conventional filter-based control methods suffer from the drawback of requiring an extended time period to reach a steady state. To address this problem, an ANN is applied to calculate the unbalanced current reference and enhance dynamic performance. Additionally, because of the periodic incorrect output inherent in the ANN, applying it to a proportional–integral controller would result in an error being directly reflected in the current reference. In the aforementioned problem, an ANN is applied to the dq0 coordinate system current controller to compensate for the periodic incorrect output in the current reference calculation. The proposed ANN-based unbalanced current compensation method is validated through PSIM simulations and experiments.

Radiation therapy for treating shallow tumors is challenging, necessitating the use of boluses. This study introduces the first application of the life-casting method to fabricate patient-specific bolus molds from gypsum sheets, comparing them with commercial boluses. Our developed boluses reduced the air gap between the skin and bolus by 77.62% compared to that of commercial boluses. In vivo dosimetry using the patient-specific bolus demonstrated better results compared to using a commercial bolus. When using the commercial bolus, the mean %Diff and max %Diff were 1.10 ± 0.61%, respectively, and 2.00% for three-dimensional conformal radiation therapy (3D-CRT) and 7.19 ± 1.90% and 10.14% for volumetric modulated arc therapy (VMAT), respectively. Contrastingly, our developed bolus demonstrated more accurate dose delivery with a mean %Diff and max %Diff of 0.82 ± 0.61% and 1.69% for 3D-CRT and 3.42 ± 1.01% and 5.03% for VMAT, respectively. Furthermore, the standard deviation between the measurements was more than 50% lower when using a patient-specific bolus than when using a commercial bolus. These results show that our bolus reduces air gaps, improves the accuracy of bolus positioning, and enhances the precision of dose delivery compared with the performance of commercial boluses. Therefore, the developed bolus is expected to be valuable in clinical applications.

Recently, the establishment of technical standards for grid connection has gained interest in academia and industry. These standards have focused on the reactive power control function of the grid-connected inverter and maintenance of grid operation, and include detailed information about the grid support function. However, remote control communication and control devices for grid support functions, and other distributed sources, such as wind power and energy storage systems, other than inverters have not been addressed. In this paper, the control of the interlinking converter (ILC) in a hybrid microgrid considering low voltage ride-through (LVRT) among grid support functions is investigated. The proposed method consists of an energy management system considering LVRT and a cooperative control scheme. In the energy management system, an algorithm capable of mode selection was constructed by applying the LVRT curve. Then, considering the LVRT situation, the allowable reactive power range of the ILC was mathematically analyzed through the cooperative control of the energy storage device and the ILC. The proposed method enables us to perform active and reactive power control of the ILC in a hybrid distribution network, considering the power factor under various conditions. This functionality, such as supplying reactive power, significantly contributes to the enhanced grid resilience with distributed power sources, including renewable energy. The proposed strategies were verified through experiments after configuring an experimental set of distributed power sources.